Abstract
Traditional methods for stabilizing temperature-sensitive biomolecules, such as lyophilization and cold storage, have significant drawbacks, including high costs, logistical complexities, and potential delays in research and product development. Capillary-mediated vitrification (CMV) is a technique that addresses these challenges by enabling the stabilization of a wide range of biomolecules and mixtures in the fraction of the time it takes to lyophilize.
In this webinar, our panel of experts will present recent findings on biomolecule stability and activity following application of the CMV process. Industry experts will be discussing the biophysical characteristics of CMV-stabilized antibodies and the technology’s impact to simplify complex assay workflows by stabilizing multiple reagents as a single mastermix.
- Current biomolecule storage methods rely on freezing or lyophilization – which have a high risk of failure and are cost intensive.
- A novel, alternative method called capillary-mediated vitrification (CMV) achieves stabilization without freezing.
- Results of application of CMV to reagents and molecules of interest will be reviewed.
- Implications for economic impact and market growth will be discussed
Speaker: Mary Retzlaff, Ph.D.
Chief Scientific Officer, Upkara
Mary Retzlaff is the Chief Scientific Officer at Upkara. Mary received her Bachelor’s degree in chemistry from Princeton University and her Ph.D from the University of Illinois Urbana-Champaign.  Prior to Upkara, Mary spent 20 years serving in a variety of roles supporting vaccine development at Merck Research Laboratories.
Speaker: Ron Bowsher, Ph.D.
Chief Scientific Officer and Partner, B2S Life Sciences
Dr. Bowsher is a partner and CSO at B2S Life Sciences. He is a Fellow of the American Association of Pharmaceutical Scientists and has spent > 4 decades in the pharmaceutical industry (Lilly Research Labs, 30+ years), CRO (LINCO/Millipore, 10+ years), and nearly 10 years at B2S Life Sciences, a unique bioanalytical CRO with a core mission in custom critical reagents.
Speaker: Alyssa Cieslak
Scientist II, B2S Life Sciences
Alyssa Cieslak is a Scientist on the Custom Reagent Team at B2S Life Sciences. Her team specializes in generating pharma-grade critical reagents to be used in PK/ADA and diagnostic assays. She earned her BA in Chemistry from Indiana University-Indianapolis. She enjoys using her multidisciplinary scientific skills to solve problems and facilitating biologics drug development programs for clients.
Speaker: Gabriela Pikul
Scientist, AssayQuant Technologies, Inc.
Gabriela Pikul is a scientist within the Inventory Management and Automation Services (IMAS) group at AssayQuant Technologies located Marlborough, MA. She is responsible for automated process development, implementation, and quality control in addition to the management of a high-throughput kinase inventory to support AssayQuant’s KinSight™ kinome profiling service. She enjoys evaluating innovative ways to simplify workflows, incorporate automation, and increase efficiency in the lab. Previously, Gabie worked in Compound Management at Pfizer (Groton, CT) supporting small molecule drug discovery and in Core Automation at Bristol Myers Squibb (Hopewell, NJ) automating bench top assays across lead optimization.
